Stocks Health care NMTC
NASDAQ · Health careNEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp brought in $9.5M of revenue over the twelve months to June 30, 2026, up 42.8% from a year earlier. It posted a net loss of $7.4M. In fiscal 2025 capital spending exceeded operating cash flow by $2.9M. At June 30, 2026 it held $2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about NEUROONE MEDICAL TECHNOLOGIES Corp
- Net worth
- NEUROONE MEDICAL TECHNOLOGIES Corp has a market value (market cap) of $7.3M at the latest share price, and shareholders' equity of $3.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $9.1M (+163.5% year on year), with a net loss of $3.6M. Over the 12 months to June 30, 2026: revenue $9.5M, net loss $7.4M.
- Cash flow
- In fiscal 2025 operations used $2.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- NEUROONE MEDICAL TECHNOLOGIES Corp's next report is expected around December 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What NEUROONE MEDICAL TECHNOLOGIES Corp does
NEUROONE MEDICAL TECHNOLOGIES Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker NMTC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9.1M | -$3.6M | -$0.09 | -$2.9M |
| 2024 | $3.5M | -$12.3M | -$0.46 | -$11.1M |
| 2023 | $2M | -$11.9M | -$0.65 | -$13.3M |
| 2022 | $171.2K | -$10M | -$0.63 | -$7.8M |
| 2021 | $178.1K | -$9.9M | -$0.93 | -$8.7M |
| 2020 | n/a | -$13.6M | -$2.52 | -$3.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NMTC ranks in Health care
Latest SEC filings
What NEUROONE MEDICAL TECHNOLOGIES Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Quarterly results8-KNeuroOne reported preliminary fourth quarter product revenue of approximately $3.8 million and secured a record $4.5 million purchase order.
- August 27, 2026Other event 8-K
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $2M versus the same quarter last year; diluted EPS -$0.28 versus -$0.19.
- August 13, 2026
- July 14, 2026Passive stake changed SCHEDULE 13G/A
- June 12, 2026Other event 8-K
- June 12, 2026Quarterly report (amended) 10-Q/A · period to March 31, 2026Revenue rose 34% to $1.9M versus the same quarter last year; diluted EPS -$0.28 versus -$0.44.
- May 29, 2026
- May 29, 2026
- May 22, 2026
Insider trades
What the people running NEUROONE MEDICAL TECHNOLOGIES Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $67K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 27, 2026 | Wambeke David J.Chief Business Officer | Bought | 33,333 | $67K |
| June 30, 2026 | Christianson MarkMarket Development Director | Sold | 10,000 | $31.8K |
| April 3, 2026 | Buckman PaulDirector | Received as pay | 41,929 | - |
| April 3, 2026 | Mathiesen Jeffrey SDirector | Received as pay | 41,929 | - |
| April 3, 2026 | Andrle EdwardDirector | Received as pay | 41,929 | - |
| April 3, 2026 | Mills Jason RichardDirector | Received as pay | 41,929 | - |
| March 31, 2026 | Rosa David ACEO and President, Director | Shares withheld for tax | 2,458 | $1.9K |
| March 31, 2026 | Christianson MarkBusiness Development Director | Shares withheld for tax | 253 | $196.6 |
Who owns NMTC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Merchant Adventure Fund, L.P.13G, passive | 13.6% | February 4, 2025 |
| Brian Pratt13G, passive with 1 related filers | 12.5% | July 14, 2026 |
| Bleichroeder LP13G, passive with 2 related filers | 8.03% | August 14, 2025 |
| Laurence W. Lytton13G, passive | 6.6% | November 25, 2024 |
Largest institutional holders
Insiders
8 insiders reported holding 1,971,659 shares in total, about $1.6M at the last price.
| Holder | Shares |
|---|---|
| Rosa David ACEO and President, Director | 1,080,132 |
| Wambeke David J.Chief Business Officer | 199,999 |
| Buckman PaulDirector | 178,733 |
| Mathiesen Jeffrey SDirector | 156,343 |
| Mertens SteveChief Technology Officer | 152,141 |
| Andrle EdwardDirector | 133,932 |
| Mills Jason RichardDirector | 49,687 |
| Christianson MarkMarket Development Director | 20,692 |
Questions about NMTC
What does NEUROONE MEDICAL TECHNOLOGIES Corp do?
NEUROONE MEDICAL TECHNOLOGIES Corp is a company in the Health care sector, listed on NASDAQ as NMTC. Its shares trade on NASDAQ under the ticker NMTC.
What is NEUROONE MEDICAL TECHNOLOGIES Corp's net worth?
NEUROONE MEDICAL TECHNOLOGIES Corp has a market value (market cap) of $7.3M at the latest share price, and shareholders' equity of $3.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NEUROONE MEDICAL TECHNOLOGIES Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $7.4M on revenue of $9.5M.
How much revenue does NEUROONE MEDICAL TECHNOLOGIES Corp make?
Over the twelve months to June 30, 2026 NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $9.5M. That is 42.8% more than a year earlier.
When did NEUROONE MEDICAL TECHNOLOGIES Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the quarterly results from October 5, 2026.
When is NEUROONE MEDICAL TECHNOLOGIES Corp's next earnings report?
NEUROONE MEDICAL TECHNOLOGIES Corp's next report is expected around December 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NMTC with
Follow NMTC
Get an email when NEUROONE MEDICAL TECHNOLOGIES Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NEUROONE MEDICAL TECHNOLOGIES Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.